{"ModuleTitle": "Company Description", "CompanyName": "Vanda Pharmaceuticals Inc.", "Symbol": "VNDA", "Address": "2200 PENNSYLVANIA AVE NW SUITE 300E, WASHINGTON, District of Columbia, 20037, United States of America", "Phone": "202-734-3400", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Vanda Pharmaceuticals Inc. (we, our, the Company or Vanda) is a leading global\r\nbiopharmaceutical company focused on the development and commercialization of\r\ninnovative therapies to address high unmet medical needs and improve the lives\r\nof patients.\r\nWe strive to advance novel approaches to bring important, new medicines to\r\nmarket through responsible innovation. We are committed to the use of\r\ntechnologies that support sound science, including genetics and genomics, in\r\ndrug discovery, clinical trials and the commercial positioning of our products.\r\nOur commercial portfolio is currently comprised of two products, HETLIOZ\u00ae for\r\nthe treatment of Non-24 and Fanapt\u00ae for the treatment of schizophrenia. HETLIOZ\u00ae\r\nis the first treatment for Non-24 approved by the FDA.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f26%2f0001347178-20-000003.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Kevin Moran", "title": "Chief Financial Officer, Treasurer & VP"}, {"name": "Mihael Hristos Polymeropoulos", "title": "President, Chief Executive Officer & Director"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}